Navigation Links
Almac Discovery and Queen's launch £13M cancer drug discovery partnership
Date:9/4/2013

A new 13 million partnership to accelerate cancer-focused drug discovery in Northern Ireland has been launched by Enterprise Minister Arlene Foster MLA.

As part of the project, Queen's and Almac Discovery have announced the scheduling of a phase one clinical trial for ovarian cancer, involving the first novel cancer drug fully developed in Northern Ireland.

Involving up to 60 ovarian cancer patients, the drug being trialled has been created as a result of an earlier collaboration between Almac Discovery and Professor Tracy Robson from the School of Pharmacy at Queen's.

Explaining about the trial, Professor Robson said: "This latest trial involves a new treatment for cancer known as ALM201, which rather than attacking tumours directly, prevents the growth of new blood vessels in tumours, starving them of oxygen and nutrients and thereby preventing their growth. It targets tumours by an entirely different pathway to those treatments currently approved."

Alan Armstrong, CEO of Almac added: "Bringing new treatments to patients is a complex process. The announcement today of a new clinical trial, which is the result of a previous partnership between Almac and Queen's School of Pharmacy, is a timely illustration of how collaboration between the University and industry is already creating novel approaches to cancer therapy which have a very real chance of helping patients."

At today's event, Enterprise Minister Arlene Foster, said: "This significant investment in research and development will enhance collaboration between academia and industry. This will ensure the investment is maximised, that research is effectively commercialised and that ultimately, enhanced treatment solutions are made available to cancer patients.

"The fact that Almac and Queen's are engaged in such ground-breaking research here in Northern Ireland is something that we should be extremely proud of. It will reinforce our position as a leader in research and development for the health and life sciences sector."

It was also announced today that a new CCRCB/Almac Discovery joint programme in Cancer Drug Discovery will bring researchers from Queen's University Belfast's Centre for Cancer Research and Cell Biology (CCRCB) and scientists from Almac Discovery together to translate research discoveries into treatments for patients.

The two projects represent a total investment of 13M, with 7 million of support offered by Invest Northern Ireland, which includes part funding from the European Regional Development Fund.

As a result of the joint programme, 17 scientists from Almac Discovery have been seconded to Queen's CCRCB in an industry led venture. The discovery team will work to identify parts of tumours which are susceptible to treatment by cancer drugs and to then develop the new drugs to target them.

The partnership will also enable new approaches to selecting those patients who will be most likely to respond to the new drugs, and to create the technologies needed to deliver the drugs directly to the tumour site in the patient.

The new discovery programme is being led by Professor Tim Harrison, Vice President of Discovery Chemistry with Almac Discovery. As part of this partnership, Professor Harrison has been appointed McClay Chair of Medicinal Chemistry at Queen's for the next three years.

Commenting on the new partnership, he said: "While Almac Discovery and Queen's have already been successfully collaborating for a number of years, this exciting new programme is bringing together for the first time, under one roof, some of our most talented scientists. As a result we expect to see an increase in both the breadth of drug targets we are able to identify and a subsequent increase in the development of potential therapeutics for patients."


'/>"/>

Contact: Lisa McElroy
lisa.mcelroy@qub.ac.uk
44-028-909-75384
Queen's University Belfast
Source:Eurekalert

Related medicine news :

1. Shapeshifting computer program will open up drug discovery for tricky disease targets
2. Vaginal Mesh Lawsuits Proceed Against Ethicon, as Bernstein Liebhard LLP Notes Order for Discovery Conferences in Federal Ethicon Litigation
3. Transvaginal Mesh Multidistrict Litigation Update: Court Issues New Pretrial Order that Moves Ethicon Inc.’s Discovery Forward, Notes Parker Waichman
4. ChanTest Announces Third User Meeting: Partnerships in Drug Discovery
5. Voices Against Brain Cancer Comments on Discovery of Nano Drug That May Aid in Treatment of Brain Tumors
6. An important discovery at the Montreal Heart Institute: A new approach to treat the most common heart valve disease in Western countries
7. Voices Against Brain Cancer Comments on Discovery of a Cause of Resistance to Therapy in Cases of Brain Cancer
8. Voices Against Brain Cancer Comments on Recent Discovery in Ongoing Brain Cancer Research
9. MessageSolution Showcases its Cloud Archiving and eDiscovery Platform at HostingCon 2013, Introduces its Enhanced MSP Partner Program
10. The Discovery House Supports Cancer Awareness and Cure
11. Laboratory Automation Market: 2017 Equipment & Software, Drug Discovery, Clinical Diagnostics, Genomics & Proteomics Analysis in New Research Reports at RnRMarketResearch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Ill. (PRWEB) , ... October ... ... Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer ... healthcare professionals on guideline updates for the primary prevention of cardiovascular diseases ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many ... event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids ... of all ages; it is a non-competitive, non-timed event, which is all about having ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
(Date:9/12/2017)... reviews on the independent review site Consumer Affairs have ... hearing aids, ranking it higher than Miracle Ear ™, Beltone™, ... ... Aids ... that provides high performance, state-of-the-art, German-engineered hearing aids directly to consumers ...
Breaking Medicine Technology: